A Game-Changer in HIV Prevention: The Injectable PrEP
In a significant advancement in the fight against HIV, the FDA has approved Apretude (cabotegravir extended-release injectable suspension) for pre-exposure prophylaxis (PrEP) to prevent HIV infection. This approval marks a pivotal shift in HIV prevention strategies, offering a new option for those at risk of HIV that doesn’t require a daily pill. The Breakthrough Apretude…